Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Regulatory agreement, secured with partner KYORIN Pharmaceutical Co., Ltd., marks the first time Hyfe's automated CoughMonitor Suite will serve as a primary endpoint in a pivotal clinical trial - a precedent for objective digital endpoints in regulated drug and device development.
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
11.09.2021
The Era of Cough as a major tool for diagnosis using the absolutely astounding power of the smartphone is upon us!A fascinating article just published by WSJ's Betsy Mckay. It highlights Hyfe's efforts to contribute to global public health with Diagnostic Cough Acoustics using the power of artificial intelligence running on the common, though powerful smartphone.
Read the entire article here!
Article by: BETSY MCKAY
Illustration by: BRIAN STAUFFER
